ProKidney Corp. Files 8-K/A Amendment
Ticker: PROK · Form: 8-K/A · Filed: Mar 18, 2024 · CIK: 1850270
| Field | Detail |
|---|---|
| Company | Prokidney Corp. (PROK) |
| Form Type | 8-K/A |
| Filed Date | Mar 18, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $620,000, $20,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, amendment
TL;DR
ProKidney filed an 8-K/A amendment covering director changes and compensation, with financial updates.
AI Summary
ProKidney Corp. filed an amendment (8-K/A) on March 18, 2024, related to events from November 10, 2023. This filing concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes financial statements and exhibits.
Why It Matters
This amendment provides updated information regarding corporate governance and executive compensation, which can impact investor confidence and the company's operational direction.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings, especially those concerning executive and director changes, can signal internal shifts or require clarification, potentially introducing uncertainty.
Key Numbers
- 20231110 — Date of Earliest Event Reported (This amendment relates to events that occurred on this date.)
- 20240318 — Filing Date (The date this amendment was officially filed with the SEC.)
Key Players & Entities
- PROKIDNEY CORP. (company) — Filer
- Social Capital Suvretta Holdings Corp. III (company) — Former Company Name
- 2000 Frontis Plaza Blvd. Suite 250, Winston-Salem, North Carolina 27103 (location) — Principal Executive Office Address
FAQ
What specific officer or director positions were affected by the events of November 10, 2023?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but specific names and roles are not detailed in the provided excerpt.
What are the key details of the compensatory arrangements mentioned?
The excerpt states that compensatory arrangements of certain officers are covered, but the specific terms or amounts are not provided in this section of the filing.
Why is this filing an amendment (8-K/A) and not an initial 8-K?
This is an amendment (8-K/A) because it is correcting or supplementing information previously filed in an earlier report, specifically related to events on November 10, 2023.
What is the significance of the former company name 'Social Capital Suvretta Holdings Corp. III'?
This indicates that ProKidney Corp. was formerly known by this name, with a name change occurring on March 10, 2021.
What type of business is ProKidney Corp. primarily involved in?
ProKidney Corp. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with the SIC code [2836].
Filing Stats: 821 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2024-03-18 16:05:57
Key Financial Figures
- $0.0001 — h registered Class A ordinary shares, $0.0001 par value per share PROK The Nasdaq
- $620,000 — pay Dr. Bertram severance pay equal to $620,000, (ii) Dr. Bertram will be eligible to r
- $20,000 — the Separation Agreement up to a cap of $20,000, and (v) subject to the terms of the ap
Filing Documents
- prok-20231110.htm (8-K/A) — 43KB
- prok-ex10_2.htm (EX-10.2) — 62KB
- 0000950170-24-032821.txt ( ) — 241KB
- prok-20231110.xsd (EX-101.SCH) — 26KB
- prok-20231110_htm.xml (XML) — 6KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The exhibits filed as part of this Current Report on Form 8-K are listed in the index to exhibits immediately preceding the signature page to this Current Report on Form 8-K, which index to exhibits is incorporated herein by reference. Exhibit No. Description of Exhibit 10.2 Separation Agreement, dated March 13, 2024, by and between ProKidney, LLC and Tim Bertram, Ph.D. 104 Cover Page Interactive Data File (embedded within Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROKIDNEY CORP. Date: March 18, 2024 By: /s/ Todd Girolamo Name: Todd Girolamo Title: Chief Legal Officer